Related Experiment Video
Updated: Oct 8, 2025
Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging
Published on: December 15, 2014
THE ROLE OF THE APPARENT DIFFUSION COEFFICIENT OF THE BIPARAMETRIC MRI AS AN IMAGING MARKER OF PROSTATE CANCER
Yu O Mytsyk1, A Ts Borzhiyevskyy1, Yu S Kobilnyk1
1Danylo Halytsky Lviv National Medical University, 69 Pekarska Str., Lviv, 79010, Ukraine.
Abstract:
Prostate cancer (PCa) is the most common malignancy in men. The role of the apparent diffusion coefficient (ADC)of biparametric MRI (biMRI) which is a study without the use of dynamic contrast enhancement (DCE), in detectionof PCa is still not comprehensively investigated.
Objective:
The goal of the study was to assess the role of ADC of biMRI as an imaging marker of clinically significant PCaMaterials and methods. The study involved 78 men suspected of having PCa. All patients underwent a comprehensive clinical examination, which included multiparametric MRI of the prostate, a component of which was biMRI. TheMRI data was evaluated according to the PIRADS system version 2.1.
Results:
The distribution of patients according to the PIRADS system was as follows: 1 point - 9 (11.54 %)patients, 2 points - 12 (15.38 %) patients, 3 points - 25 (32.05 %) patients, 4 points - 19 (24.36 %) patients and5 points - 13 (16.67 %) patients. In a subgroup of patients with 5 points, clinically significant PCa was detected in 100 % of cases. In the subgroup of patients with tumors of 4 points clinically significant PCa was diagnosed in 16of 19 (84.21 %) cases, and in 3 (15.79 %) patients - clinically insignificant tumor. In the subgroup of patients with3 points, clinically significant PCa was diagnosed in 11 of 25 (44.0 %) cases, in 8 (32.0 %) patients - clinicallyinsignificant tumor and in 6 (24.0 %) patients - benign prostatic hyperplasia. PCa with a score of 7 on the Gleasonscale showed significantly lower mean values of ADC of the diffusion weighted MRI images compared to tumors witha score of < 7 on the Gleason scale: (0.86 ± 0.07) x 103 mm2/s vs (1.08 ± 0.04) x 103 mm2/s (р < 0.05).
Conclusions:
The obtained results testify to the high informativeness of biMRI in the diagnosis of prostate cancer.The use of ADC allowed to differentiate clinically significant and insignificant variants of the tumor, as well asbenign changes in prostate tissues and can be considered as a potential imaging marker of PCa.
Insights
Biparametric MRI (biMRI) using apparent diffusion coefficient (ADC) effectively identifies clinically significant prostate cancer (PCa). ADC values help differentiate PCa from benign conditions, aiding in diagnosis.
Area of Science:
- Radiology
- Oncology
- Medical Imaging
Background:
- Prostate cancer (PCa) is a prevalent malignancy in men.
- The diagnostic role of apparent diffusion coefficient (ADC) from biparametric MRI (biMRI) for PCa detection requires further investigation.
Purpose of the Study:
- To evaluate the efficacy of ADC in biMRI as an imaging biomarker for clinically significant PCa.
- To assess the ability of ADC to differentiate between significant PCa, insignificant PCa, and benign prostate conditions.
Main Methods:
- The study included 78 men with suspected PCa undergoing multiparametric MRI, including biMRI.
- Prostate MRI data were analyzed using the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1.
- Apparent diffusion coefficient (ADC) values were measured and correlated with Gleason scores and histopathological findings.
Main Results:
- Higher PI-RADS scores correlated with increased likelihood of clinically significant PCa (e.g., 100% for PI-RADS 5).
- ADC values were significantly lower in high-grade PCa (Gleason score ≥ 7) compared to lower-grade tumors (0.86 vs. 1.08 x 10⁻³ mm²/s, p < 0.05).
- ADC analysis helped distinguish between clinically significant PCa, insignificant PCa, and benign prostatic hyperplasia.
Conclusions:
- Biparametric MRI (biMRI) demonstrates high informativeness in diagnosing prostate cancer.
- ADC measurements are valuable for differentiating clinically significant PCa from insignificant tumors and benign prostate changes.
- ADC holds potential as a non-invasive imaging marker for prostate cancer detection and characterization.
